CLEC10A is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in lung adenocarcinoma

He, Min; Han, Ying; Cai, Changjing; Liu, Ping; Chen, Yihong; Shen, Hong; Xu, Xingyuan; Zeng, Shan

doi:10.1111/jcmm.16416

Cited by 24 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lower CLEC10A expression was found to be associated with poorer prognosis. Some similar findings were reported in lung carcinoma, in a bioinformatics analysis on LUAD data downloaded from TCGA and Gene Expression Omnibus (12). Therefore, CLEC10A may be applied as a potentially powerful prognostic biomarker in BC clinical management.…”

Section: Discussionsupporting

confidence: 74%

“…The ability of CLEC10A in promoting the antitumor activity of immune cells has been garnering attention (10,11), where it was proposed to be a target for cancer immunotherapy (8). Lower expression levels of CLEC10A in lung cancer have been reported to be associated with poorer clinical prognosis (12). Furthermore, a previous study based on artificial intelligence algorithms revealed that CLEC10A can be applied as prognostic biomarkers for BC (13).…”

Section: Clec10a Can Serve As a Potential Therapeutic Target And Its ...mentioning

confidence: 99%

See 1 more Smart Citation

CLEC10A can serve as a potential therapeutic target and its level correlates with immune infiltration in breast cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common malignant cancers in females worldwide and greatly threatens women's health. The C-type lectin domain family 10 member A (CLEC10A) is a member of the C-type lectin receptor family that has been previously reported to promote the antitumor activity of immune cells. In the present study, the potential prognostic value of CLEC10A expression in BC was assessed using data from The Cancer Genome Atlas online database. Differences in the mRNA expression levels of CLEC10A between BC and normal tissues were then analyzed using the Tumor Immune Estimation Resource (TIMER) platform and the University of Alabama at Birmingham Cancer data analysis portal. Reverse transcription-quantitative PCR was performed to validate the results of this analysis. The Kaplan-Meier plotter database was used to evaluate the association between the mRNA expression levels of CLEC10A and clinical prognosis of BC. Based on the association between the mRNA expression levels of CLEC10A and the tumor immune microenvironment, the TIMER platform and the Tumor and Immune System Interaction Database website were utilized to assess the correlation between CLEC10A expression and the degree of tumor immune cell infiltration. The present study revealed that CLEC10A expression was significantly lower in BC tissues compared with that in normal tissues, which was in turn associated with poorer clinical outcomes. This suggested that lower CLEC10A expression levels were associated with unfavorable prognosis in BC. In addition, the expression level of CLEC10A was found to be positively associated with the level of different tumor-infiltrating immune cells in BC, including CD8 T cells, B cells, macrophages and NK cells which, was in turn closely correlated with some gene markers such as CD19, CD8A, KIR2DS4 and PTGS2. These results suggest that the relationship between lower CLEC10A expression level and poor prognosis in BC may be due to the role of CLEC10A in the tumor immune microenvironment. In conclusion, CLEC10A may be a potential biomarker that can be used to efficiently predict prognosis in patients with BC.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Clec10a Can Serve As a Potential Therapeutic Target And Its ...mentioning

confidence: 99%

CLEC10A can serve as a potential therapeutic target and its level correlates with immune infiltration in breast cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…To further explore the interactions between immune system and LOX family members that are associated with poor prognosis, the TISIDB database (http://cis.hku.hk/TISIDB) was used. TISIDB is a web portal for analyzing immune system and tumor interaction, including nearly one thousand reported immunerelated anti-tumor genes, etc., and immunological data gathered from seven public databases (129)(130)(131). Here, TISIDB was used for exploring the immunomodulators associated with LOX family members in LC.…”

Section: Immune Cell Infiltration Of Lox Family Members In Lcmentioning

confidence: 99%

Diagnostic Value, Prognostic Value, and Immune Infiltration of LOX Family Members in Liver Cancer: Bioinformatic Analysis

Sun

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundLiver cancer (LC) is well known for its prevalence as well as its poor prognosis. The aberrant expression of lysyl oxidase (LOX) family is associated with liver cancer, but their function and prognostic value in LC remain largely unclear. This study aimed to explore the function and prognostic value of LOX family in LC through bioinformatics analysis and meta-analysis.ResultsThe expression levels of all LOX family members were significantly increased in LC. Area under the receiver operating characteristic curve (AUC) of LOXL2 was 0.946 with positive predictive value (PPV) of 0.994. LOX and LOXL3 were correlated with worse prognosis. Meta-analysis also validated effect of LOX on prognosis. Nomogram of these two genes and other predictors was also plotted. There was insufficient data from original studies to conduct meta-analysis on LOXL3. The functions of LOX family members in LC were mostly involved in extracellular and functions and structures. The expressions of LOX family members strongly correlated with various immune infiltrating cells and immunomodulators in LC.ConclusionsFor LC patients, LOXL2 may be a potential diagnostic biomarker, while LOX and LOXL3 have potential prognostic and therapeutic values. Positive correlation between LOX family and infiltration of various immune cells and immunomodulators suggests the need for exploration of their roles in the tumor microenvironment and for potential immunotherapeutic to target LOX family proteins.

show abstract

“…Lung cancer is divided into small cell lung cancer and non-small cell lung cancer (NSCLC). Lung adenocarcinoma (LUAD) is the largest subgroup of NSCLC [2,3]. Despite improvements in systemic treatments for patients, the 5-year survival rate of LUAD patients is 15% [4].…”

Section: Introductionmentioning

confidence: 99%

GRAP2 is a Prognostic Biomarker and Correlated with Immune Infiltration in Lung Adenocarcinoma

Song

Deng

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: GRAP2 is an adaptor protein involved in leukocyte-specific protein-tyrosine kinase signaling; however, the prognostic value of GRAP2 and its correlation with immune cell infiltration in lung adenocarcinoma (LUAD) remain unclear.Methods: All original data were downloaded from the TCGA database and integrated via R 3.2.2. GRAP2 expression was explored with the TCGA and TIMER databases. We evaluated the influence of GRAP2 on clinical prognosis using the Kaplan-Meier plotter, Gene Expression Omnibus (GEO) database and GEPIA database. Correlations between GRAP2 and cancer immune characteristics were analyzed via TIMER and TISIDB databases. Finally, we confirmed the expression of GRAP2 in LUAD by immunohistochemistry staining.Results: Transcription levels of GRAP2 were significantly lower in several human cancers, including LUAD, than in adjacent normal tissues. We also found that tumor tissues have lower protein expression levels of GRAP2 compared with adjacent normal tissues in LUAD by immunohistochemistry staining. The down-regulated GRAP2 was associated with poorer overall survival, pathologic stage, T stage, N stage and primary therapy outcome in LUAD. Mechanically, we identified a hub gene that included a total of 91 GRAP2 co-expressed genes, which were tightly associated with immune response in LUAD. GRAP2 expression was positively correlated with infiltrating levels of B cells, CD8+ T cells, dendritic cells, eosinophils, macrophages, mast cells, Th2 cells, Th1 cells, Th17 cells, NK cells and neutrophils. GRAP2 expression level also affected the cumulative survival time of B cells and dendritic cells. GRAP2 expression is positively correlated with multiple immune markers, chemokines, chemokine receptors and MHC molecules of LUAD.Conclusions: These findings suggest that GRAP2 is a tumor suppressor gene and can be used as a prognostic biomarker for determining prognosis and immune infiltration in LUAD.

show abstract

CLEC10A is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in lung adenocarcinoma

Cited by 24 publications

References 38 publications

CLEC10A can serve as a potential therapeutic target and its level correlates with immune infiltration in breast cancer

CLEC10A can serve as a potential therapeutic target and its level correlates with immune infiltration in breast cancer

Diagnostic Value, Prognostic Value, and Immune Infiltration of LOX Family Members in Liver Cancer: Bioinformatic Analysis

GRAP2 is a Prognostic Biomarker and Correlated with Immune Infiltration in Lung Adenocarcinoma

Contact Info

Product

Resources

About